Program
ruzaltatug rezetecan
Also written as “adebrelimab + SHR-A2009”, “almonertinib combined with SHR-A2009” and “SHR-A2009”.
In Jiangsu HengRui Medicine’s pipeline, HER3 ADC
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Nov 1, 20248 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 87 open or running | phase 3since Nov 1, 2024 | Oct 20, 2021 | Dec 2026phase 3 · NCT06671379 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-A2009
, phase 4, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05114759 · 176 enrolled · China, Japan, South Korea
- May 24, 2022Phase 1 study in Advanced Solid TumorNCT05394818 · 19 enrolled · China
- Oct 8, 2023Phase 2 study in Advanced Solid TumorsNCT06092268 · 270 planned
- Dec 4, 2023Phase 2 study in Breast NeoplasmsNCT06222879 · 350 planned · China
- Nov 1, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06671379 · 498 enrolled · China
- Sep 12, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07183189 · 582 enrolled · China
- Sep 30, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07863167 · 660 planned · China
- Oct 19, 2026Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07895992 · 490 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06671379
- Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT05114759
- Dec 30, 2028Primary completion: phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07895992
- Dec 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07863167
TargetBeta
“HER3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1) human monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3), conjugated, via a cleavable peptide linker, to rezetecan, an exatecan derivative and cytotoxic DNA topoisomerase …”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1) human monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3), ”NCIt, by rule
Other programs on ERBB3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| patritumab deruxtecan | Merck | phase 3 | 17 |
| beruzatatug pelitecanrule | MediLink Therapeutics (Suzhou) | phase 3 | 9 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| SYS6023rule | CSPC Pharmaceutical Group | phase 2 | 2 |
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | xadcera-biopharmaceutical-suzhou-co-ltd | phase 2 | 1 |
| Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rule | hummingbird-bioscience | phase 2 | 1 |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| KHN922rule | Chengdu Kanghong Pharmaceutical Group | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07895992Non-squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | Dec 30, 2028 | 490 |
| NCT07863167Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Dec 30, 2028 | 660 |
| NCT07183189Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Nov 2032 | 582 |
| NCT06671379Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Dec 2026 | 498 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Oct 31, 2026 | 350 |
| NCT06092268Advanced Solid Tumors | 2 | Not yet recruiting | Dec 2025 | 270 |
| NCT05394818Advanced Solid Tumor · China | 1 | Completed | Apr 30, 2024 | 19 |
| NCT05114759Advanced Solid Tumors · China, Japan, South Korea | 1 | Active, not recruiting | Dec 30, 2026 | 176 |
How it is read
Names in the registry
- “adebrelimab + SHR-A2009”, 3 entries
- “almonertinib combined with SHR-A2009”, 2 entries
- “SHR-A2009”, 2 entries
- “SHR-A2009 + bevacizumab”, 1 entry
- “SHR-A2009 combined with almonertinib”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.